LIFECORE BIOMEDICAL, INC. \DE\
LFCR · XNASCIK 1005286fmd_0JJ681DWPMQP2KWJX66EVG23B6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jun 01, 2009 to Sep 30, 2026, 66 periods
Latest annual · FY2025
Millions- Total revenues
- 129
- Gross profit
- 40
- Operating income
- (17)
- Net income
- (39)
- Free cash flow
- (14)
Latest quarter · Q1 FY2027
Millions- Total revenues
- 25
- Gross profit
- 7
- Operating income
- (1)
- Net income
- (40)
- Free cash flow
- 6
Daily close · LFCRIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions6.40 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +5.0%
- Revenue, 5 yearsFY2020 to FY2025
- -4.2%
- Net income, 5 yearsFY2020 to FY2025
- n/m
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $128.9 million | $128.3 million | +0.5% | 10-K 2025-08-07 · proof |
| Gross profit | $40.3 million | $41.9 million | -3.7% | 10-K 2025-08-07 · proof |
| Operating income | -$17.2 million | -$8.8 million | 10-K 2025-08-07 · proof | |
| Net income | -$38.7 million | $12 million | -422.3% | 10-K 2025-08-07 · proof |
| Cash from operating activities | -$206,000 | $257,000 | -180.2% | 10-K 2025-08-07 · proof |
| Free cash flow | -$13.6 million | -$18.1 million | 10-K 2025-08-07 · proof | |
| Total assets | $239.3 million | $254 million | -5.8% | 10-K 2025-08-07 · proof |
| Total liabilities | $191.9 million | $200.1 million | -4.1% | 10-K 2025-08-07 · proof |
| Cash and cash equivalents | $8.3 million | $8.5 million | -2.3% | 10-K 2025-08-07 · proof |
| Total debt | $133.9 million | $101.8 million | +31.6% | 10-K 2025-08-07 · proof |
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s revenue in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported revenue of $128.9 million for fiscal 2025 (the year ended May 25, 2025), against $128.3 million the year before (+0.5%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s gross profit in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported gross profit of $40.3 million for fiscal 2025 (the year ended May 25, 2025), against $41.9 million the year before (-3.7%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s operating income in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported operating income of -$17.2 million for fiscal 2025 (the year ended May 25, 2025), against -$8.8 million the year before. Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s net income in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported net income of -$38.7 million for fiscal 2025 (the year ended May 25, 2025), against $12 million the year before (-422.3%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s cash from operating activities in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported cash from operating activities of -$206,000 for fiscal 2025 (the year ended May 25, 2025), against $257,000 the year before (-180.2%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What was LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s free cash flow in fiscal 2025?
- LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported free cash flow of -$13.6 million for fiscal 2025 (the year ended May 25, 2025), against -$18.1 million the year before. Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What are LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s total assets?
- As of May 25, 2025, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported total assets of $239.3 million, against $254 million a year earlier (-5.8%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What are LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s total liabilities?
- As of May 25, 2025, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported total liabilities of $191.9 million, against $200.1 million a year earlier (-4.1%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What are LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s cash and cash equivalents?
- As of May 25, 2025, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported cash and cash equivalents of $8.3 million, against $8.5 million a year earlier (-2.3%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
- What is LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)'s total debt?
- As of May 25, 2025, LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported total debt of $133.9 million, against $101.8 million a year earlier (+31.6%). Source: the 10-K filed with the SEC on Aug 7, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:LFCR&period_type=annual&limit=5"Information only, not investment advice.